Newton Earns CE Mark for Headache-Relief Prescription Lens

Its Neurolens is designed to relieve symptoms associated with ocular misalignment.

Hand holding black-framed eyeglasses in front of an eye chart for vision testing
Liudmila Chernetska/iStock

Newton, the eye care technology company behind Neurolens, today announced that the Neurolens N3 has received CE marking under the European Union Medical Device Regulation (EU MDR). The certification, issued by Intertek Medical Notified Body AB, clears the N3 for commercialization across the European Union and European Economic Area.

The N3 is the measurement system that powers the Neurolens experience. It gives eye care professionals an objective view of how a patient's eyes align, providing the data needed to prescribe Neurolens with Contoured Prism technology. Key features include:

  • Objective ocular alignment measurement at distance and near, using eye-tracking technology to capture how the eyes align and work together
  • Headset-based design that creates a consistent, controlled testing environment in a compact footprint suited to any pre-test area
  • Workflow that fits into the pre-test routine: the automated test takes just a few minutes and can be run by trained staff
  • Prescription-ready data that translates directly into a Neurolens Contoured Prism prescription

Neurolens is designed to relieve symptoms associated with ocular misalignment, including headaches, neck and shoulder pain and motion sickness, offering a non-pharmaceutical option for patients.

Neurolens is backed by peer-reviewed clinical evidence. In a randomized, double-masked, crossover clinical trial published in Translational Vision Science & Technology (2024), patients experienced an average 5-point reduction in HIT-6 scores, a validated measure of headache impact on daily life, after four weeks of Neurolens wear.

Results in everyday practice have been just as strong: in a survey of wearers after 60 days, 90% reported symptom improvement.

"Achieving EU MDR certification is a major step forward for Newton and reflects the hard work and discipline our team brings to every stage of our product development, from research and clinical evaluation to quality and manufacturing," said Gregory Boisse, Sr. VP of Operations and R&D at Newton. "It represents years of collaboration and a shared commitment to patient safety, product quality, and continuous improvement. I'm incredibly proud of the people behind this achievement and excited for what it means for our future."

Newton expects to introduce Neurolens in its first European markets in 2027, with additional countries to follow. Europe will join Newton's existing markets in the United States, and Canada.

More in Devices